英科医疗: 内部审计管理制度
Zheng Quan Zhi Xing· 2025-07-08 16:12
Group 1 - The company establishes an internal audit system to enhance the quality of internal audits and protect investors' rights [1] - Internal audit is defined as an evaluation activity conducted by the company's internal audit personnel to assess the effectiveness of internal controls and risk management [1][2] - The board of directors is responsible for the establishment and effective implementation of the internal control system [1][2] Group 2 - The company has set up an internal control department as the internal audit institution, reporting to the audit committee of the board of directors [2][3] - The internal control department is tasked with checking the authenticity and completeness of financial information and the implementation of internal control systems [2][3] - Internal audit personnel must possess necessary auditing knowledge and experience in finance and management [2][3] Group 3 - The internal control department must prepare an annual internal audit work plan two months before the end of each accounting year [3][4] - The internal control department is required to report to the audit committee at least quarterly on the execution of the internal audit plan and any issues discovered [4][5] - The audit committee must supervise the internal audit department to conduct checks on high-risk investments and significant transactions at least semi-annually [4][5] Group 4 - The internal control department must promptly audit significant external investments, asset purchases or sales, guarantees, and related transactions [6][7] - The internal audit report must include evaluations of legality, risk, and effectiveness of internal control systems [9][10] - The internal control department is responsible for following up on identified internal control deficiencies and ensuring corrective measures are implemented [6][7] Group 5 - The company must disclose any significant deficiencies or risks in internal control to the stock exchange and provide details on the measures taken [5][11] - The internal control department must submit an annual internal audit report to the audit committee within three months after the end of each accounting year [5][11] - The internal control evaluation report must include the board's declaration regarding the authenticity of the internal control report [11][12]
英科医疗: 信息披露暂缓与豁免业务内部管理制度
Zheng Quan Zhi Xing· 2025-07-08 16:12
英科医疗科技股份有限公司 第一章 总则 第一条 为规范英科医疗科技股份有限公司(以下简称"公司")及其他信 息披露义务人的信息披露暂缓、豁免行为,确保公司及其他信息披露义务人依法 合规履行信息披露义务,提高信息披露质量、保护公司和投资者的合法权益,根 据《中华人民共和国公司法》(以下简称《公司法》)《中华人民共和国证券法》 (以下简称《证券法》)《深圳证券交易所创业板股票上市规则》(以下简称《上 市规则》)《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司 规范运作》(以下简称《规范运作指引》)《上市公司信息披露暂缓与豁免管理 规定》(以下简称《暂缓与豁免规定》)等法律、法规及《英科医疗科技股份有 限公司公司章程》(以下简称《公司章程》)的规定,制定本制度。 第二条 公司应当披露的信息存在《上市规则》《规范运作指引》及《暂缓 与豁免规定》规定的暂缓、豁免情形的,公司应当审慎确定信息披露暂缓、豁免 事项。对于不符合暂缓、豁免披露条件的信息,应当及时披露。 公司及相关信息披露义务人暂缓、豁免披露商业秘密后,出现下列情形之一 的,应当及时披露,并说明该信息认定为商业秘密的主要理由、内部审核程序以 及未披露 ...
英科医疗: 关联交易管理制度
Zheng Quan Zhi Xing· 2025-07-08 16:12
Core Viewpoint - The document outlines the regulations and procedures for related party transactions of Yingke Medical Technology Co., Ltd, aiming to ensure fair pricing, compliance in decision-making processes, and protection of the rights of the company and its shareholders [1][2][3]. Group 1: Related Party Identification - Related parties include both legal entities and natural persons that have significant control or ownership over the company, such as those holding more than 5% of shares [4][5]. - The company must maintain an updated list of related parties and their relationships, which should be disclosed through the securities exchange [3][4]. Group 2: Transaction Procedures - Transactions with related natural persons exceeding 300,000 yuan must be submitted for board review and disclosure [11]. - Transactions with related legal entities exceeding 3 million yuan and constituting more than 0.5% of the company's latest audited net assets must also be submitted for board review [12][13]. Group 3: Decision-Making and Disclosure - Related transactions must be approved by a majority of independent directors and disclosed to shareholders [18][19]. - The company is required to disclose details of related transactions, including pricing policies, transaction amounts, and the rationale for engaging in such transactions [30][31]. Group 4: Pricing Policies - Related party transactions must be conducted at fair prices, referencing government pricing, market prices, or reasonable cost-plus methods [22][23]. - If no comparable market prices exist, the company must provide a rationale for the pricing method used [24][25]. Group 5: Special Provisions for Daily Transactions - Daily related transactions must follow specific approval processes, especially if they exceed estimated amounts during execution [26][27]. - Agreements for daily transactions lasting over three years must be re-evaluated every three years [28]. Group 6: Reporting and Compliance - The company must report related transactions in its annual and semi-annual reports, categorizing and summarizing the transactions [15][16]. - Any significant changes in transaction terms during execution must be reported and re-evaluated [26][27].
西藏天路: 西藏天路公司章程(2025年7月修订版)
Zheng Quan Zhi Xing· 2025-07-08 16:12
章 程 (2025年7月 修订版) 西 藏 天 路 股 份 有 限 公 司 T IBET T IANLU CO . , LTD. 西藏天路 代码: 600326 公司章程 第一章 总则 第一条 为维护公司、股东和债权人的合法权益,规范公司的组织和行为,根据《中华人民共 和国公司法》(以下简称《公司法》)、《中华人民共和国证券法》(以下简称《证券法》)和其他有 关 规定,制订本章程。 第二条 西藏天路股份有限公司系依照《公司法》和其他有关规定成立的股份有限公司(以下 简称"本公司"或"公司")。 公司经西藏自治区人民政府藏政函(1999)80 号文和和西藏自治区经济贸易体制改革委员会 藏经委企复(1999)第 72 号文批准,以发起方式设立;在西藏自治区工商行政管理局注册登记, 取得营业执照,公司统一社会信用代码为 91540000710905111C。 第三条 公司于 2000 年 12 月 19 日经中国证券监督管理委员会证监发行字2000179 号文核 准,首次向社会公众发行人民币普通股 4000 万股,全部为向境内投资人发行的以人民币认购的内 资股(即人民币普通股),于 2001 年 1 月 16 日在 ...
英科医疗: 财务报告管理制度
Zheng Quan Zhi Xing· 2025-07-08 16:12
Core Points - The company establishes a financial reporting internal control system to ensure the authenticity and reliability of financial information, enhance corporate governance, and protect shareholder rights [1][2] - The financial reporting internal control applies to the company and its wholly-owned and controlled subsidiaries [1] - The financial report includes accounting statements and related disclosures, ensuring compliance with accounting laws and regulations [1][2] Management Responsibilities - The finance department is responsible for the preparation and management of financial reports, including collecting accounting information and compiling financial analysis reports [3] - The board of directors and senior management collectively ensure the authenticity and completeness of the financial reports [3][4] - Specific responsibilities are assigned to various departments to ensure accurate financial accounting and reporting [3][4] Major Financial Matters - The company adopts accounting policies based on relevant accounting standards and guidelines, with changes requiring approval from the board of directors [11][12] - Significant accounting estimates must be reviewed and approved, with any changes communicated to relevant stakeholders [7][8] - Major financial matters are assessed and reported, including impacts on financial statements and compliance with regulations [8][9] Financial Report Preparation - The finance department is tasked with preparing annual financial reports, ensuring compliance with accounting standards and legal requirements [18][19] - Accurate accounting records must be maintained, and any discrepancies must be addressed promptly [19][20] - The company must conduct asset verification and ensure all financial transactions are recorded accurately [20][21] Financial Reporting and Submission - The company must submit financial reports in a timely manner, ensuring all documents are properly formatted and signed [15][16] - Any errors in submitted reports must be corrected and communicated to relevant parties [15][16] - Financial analysis reports are prepared semi-annually to evaluate the company's performance and financial health [35][36] Financial Analysis - Financial analysis aims to evaluate the company's operational performance and profitability, identifying key influencing factors [35][36] - The analysis includes various financial ratios to assess liquidity, operational efficiency, and profitability [36][37] - The finance department is responsible for compiling and presenting financial analysis reports to the board [35][36]
华大智造: 中信证券股份有限公司关于深圳华大智造科技股份有限公司2025年度日常关联交易调整暨增加预计额度的核查意见
Zheng Quan Zhi Xing· 2025-07-08 16:12
中信证券股份有限公司 关于深圳华大智造科技股份有限公司 上海证券交易所: 中信证券股份有限公司(以下简称"中信证券")作为深圳华大智造科技股 份有限公司(以下简称"华大智造"或"公司")首次公开发行股票并在科创板 上市的保荐机构,根据《证券发行上市保荐业务管理办法》《上海证券交易所科 创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号—— 规范运作》等相关规定履行持续督导职责,对华大智造 2025 年度日常关联交易 调整暨增加预计额度事项进行了审慎核查,具体核查情况如下: 一、日常关联交易基本情况 (一)关于 2025 年度日常关联交易预计额度履行的审议程序 | | | | 截至 | 2025 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 年 5 月 | 30 | | 本次调整/ | 本次调整后 | | | 关联交易 | | | | 日已发生 | | 剩余额度(万 | 新增金额 | 2025 年全 | | 关联方 类别 | | 调整后的关联体系 | 预计额度 | 金额(万 | 元) | | ...
华大智造: 北京市君合(深圳)律师事务所关于深圳华大智造科技股份有限公司2024年限制性股票激励计划作废部分限制性股票事项的法律意见书
Zheng Quan Zhi Xing· 2025-07-08 16:12
田区中心四路 1-1 号 场第三座第 2803-04 室 邮编:518048 (86-755) 2939-5288 (86-755) 2939-5289 北京市君合(深圳)律师事务所 关于深圳华大智造科技股份有限公司 法律意见书 深圳华大智造科技股份有限公司: 北京市君合(深圳)律师事务所(以下简称"本所")接受深圳华大智造科 技股份有限公司(以下简称"公司")的委托,就公司拟作废 2024 年限制性股票 激励计划(以下简称"本次激励计划")部分限制性股票(以下简称"本次作废") 相关事项,根据《中华人民共和国公司法》 (以下简称" 《公司法》" )、《中华人民 共和国证券法》(以下简称" 《证券法》")、《上市公司股权激励管理办法》(以下 ,仅为出具本法律 意见书之目的,"中国"不包括中国香港特别行政区、中国澳门特别行政区和中 国台湾省)正式公布并实施的有关法律、法规、规范性文件和《深圳华大智造科 技股份有限公司章程》 (以下简称" 《公司章程》")的有关规定,出具本法律意见 书。 简称" 《管理办法》")、《上海证券交易所科创板股票上市规则》(以下简称" 《上 市规则》" )、《科创板上市公司自律监管指南 ...
上市公司动态 | 巨化股份预计半年度净利同比增136%-155%,华工科技上半年净利同比预增42.43%-52.03%,大洋电机拟港交所上市
Sou Hu Cai Jing· 2025-07-08 16:12
重点要闻 业绩变动原因主要由于2025年上半年实现饲料外销量约1.365万吨,同比增加 284万吨,增长率约为26%;其中海外地区同比增长率约为40%。本报告期,公 司稳步提升国内饲料产能利用率和市场份额,销量增长带来的运营效率提升、边际费用节约增强了最基本的产品竞争优势;海外地区在成熟的采购、技术、 服务等产品竞争优势基础上,结合当地养殖实际需求进行针对性改良、升级,为当地养殖户赋能,同时积极开拓新区域,销量增长及盈利水平均保持良好态 势。同时,公司披露生猪养殖业务在轻资产、控风险的养殖模式下,盈利可观;受累于上半年禽肉价格低迷,公司禽屠宰相关业务录得亏损。 华工科技上半年净利润同比预增42.43%-52.03% 华工科技(000988.SZ)公告称,预计2025年上半年归属于上市公司股东的净利润为8.9亿元至9.5亿元,同比增长42.43%至52.03%。上半年,公司所聚焦赛道的 市场主体业务大幅增长。其中,联接业务随着国内互联网及设备厂商算力需求激增,应用于算力中心建设的400G、800G等高速光模块需求快速释放,收入 和盈利较上年同期大幅增长。感知业务紧抓新能源汽车渗透率创新高和出口增长的机遇,市场占 ...
A股突发!688585,智元机器人拟入主!周三复牌!
Zheng Quan Shi Bao Wang· 2025-07-08 16:09
Core Viewpoint - The announcement from Shangwei New Materials (688585) indicates that Shanghai Zhiyuan New Technology Co., Ltd. and its core team plan to acquire at least 63.62% of the company's shares, marking a significant change in ownership and control [2][4]. Group 1: Share Acquisition Details - On July 8, SWANCOR Samoa, Zhiyuan Hengyue, and others signed a share transfer agreement, where Zhiyuan Hengyue intends to acquire 100 million unrestricted shares from SWANCOR Samoa, representing 24.99% of the total shares, for a total price of RMB 784 million [4]. - Additionally, Zhiyuan New Venture plans to acquire 2.4 million shares (0.60% of total shares) from SWANCOR Samoa, and 17.77 million shares (4.40% of total shares) from Jinfeng Investment Control [4]. Group 2: Control Changes - Following the completion of the share transfer, Zhiyuan Hengyue and Zhiyuan New Venture will collectively hold 29.99% of the shares and corresponding voting rights, leading to a change in the controlling shareholder to Zhiyuan Hengyue, with Deng Taihua becoming the actual controller of the company [5][6]. Group 3: Future Plans and Market Impact - Zhiyuan Hengyue plans to further increase its stake through a partial tender offer for an additional 149 million shares, which would account for 37.00% of the total shares [6]. - The acquisition is expected to be a landmark case for new productivity enterprises in the A-share market and the first acquisition case for embodied intelligence companies on the Sci-Tech Innovation Board [6].
华贸物流: 港中旅华贸国际物流股份有限公司2024年年度权益分派实施公告
Zheng Quan Zhi Xing· 2025-07-08 16:08
证券代码:603128 证券简称:华贸物流 公告编号:2025-017 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 本次利润分配以方案实施前的公司总股本1,309,046,494股为基数,每股派发现金红利 三、 相关日期 ? 每股分配比例 A 股每股现金红利0.174元 ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权(息)日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | A股 | 2025/7/14 | - | 2025/7/15 | 2025/7/15 | | ? 差异化分红送转: 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 30 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后,在中国证券登记结算有限责任公司上海分 公司(以下简称"中国结算上海分公司")登记在册的本公司全体股东。 | 股份类别 | 股权登记日 | | 最后交易日 | ...